LYMPHOMA, LARGE B-CELL, DIFFUSE
Clinical trials for LYMPHOMA, LARGE B-CELL, DIFFUSE explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, LARGE B-CELL, DIFFUSE trials appear
Sign up with your email to follow new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy MK-1045 takes on tough lymphomas
Disease control Recruiting nowThis study tests an experimental immunotherapy called MK-1045 in 200 people with two types of non-Hodgkin lymphoma: follicular lymphoma (slow-growing) and diffuse large B-cell lymphoma (fast-growing). Participants have already tried at least two other treatments without success. …
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for blood cancer: targeted therapy combo shows promise in phase 2 trial
Disease control Recruiting nowThis study tests whether a new drug, zilovertamab vedotin, combined with standard chemotherapy (R-CHP) works better than another approved drug combo for people with a specific type of fast-growing blood cancer called GCB diffuse large B-cell lymphoma. About 594 adults who have no…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New Dual-Targeting CAR-T therapy shows promise for tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding two newer drugs, glofitamab and polatuzumab, to standard chemotherapy (R-CHP) can improve outcomes for people with high-risk diffuse large B-cell lymphoma. About 41 adults with untreated CD20-positive lymphoma will receive the combination. The main…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Second chance: nonconforming CAR-T therapy offered to lymphoma patients
Disease control AVAILABLEThis program provides access to a CAR-T cell therapy called lisocabtagene maraleucel (liso-cel) that didn't meet all commercial quality standards. It is for adults with large B-cell lymphoma who were already prescribed liso-cel as part of their care. Patients receive chemotherapy…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New PET scan targets hidden cancers with precision
Diagnosis Recruiting nowThis study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer an…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC